Trial
NCT03672643
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
ALK or ROS1-positive NSCLC
Intervention
Crizotinib
Why stopped
The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-08